Back to search resultsSummaryRMgm-1513
|
||||||||
*RMgm-1513| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene tagging |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 27434123 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. yoelii |
| Parent strain/line | P. y. yoelii 17XNL |
| Name parent line/clone | Not applicable |
| Other information parent line | |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Speake C, Kappe SH, Krzych U, Duffy PE |
| Name Group/Department | Laboratory of Malaria Immunology and Vaccinology |
| Name Institute | National Institute of Allergy and Infectious Diseases, National Institutes of Health |
| City | Bethesda, Maryland |
| Country | USA |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-1513 |
| Principal name | PyPF3D7_0730200::myc |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | No |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not tested |
| Gametocyte/Gamete | Not tested |
| Fertilization and ookinete | Not tested |
| Oocyst | Not tested |
| Sporozoite | Not tested |
| Liver stage | The tagged protein was detected in 24h liver stages and localized in parasite cytoplasm. |
| Additional remarks phenotype | Mutant/mutation Expression of the gene is only analysed in liver stages. |
Tagged: Mutant parasite with a tagged gene| top of page | |||||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PY17X_0215700 | ||||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0730200 | ||||||||||||||||||||||||||
| Gene product | AP-4 complex subunit beta, putative | ||||||||||||||||||||||||||
| Gene product: Alternative name | |||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||||
| Name of the tag | c-myc | ||||||||||||||||||||||||||
| Details of tagging | C-terminal | ||||||||||||||||||||||||||
| Additional remarks: tagging | quadruple myc tag | ||||||||||||||||||||||||||
| Commercial source of tag-antibodies | |||||||||||||||||||||||||||
| Type of plasmid/construct | (Linear) plasmid single cross-over | ||||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||||
| Additional remarks genetic modification | The b3D-myc vector for epitope tagging genes of interest was used to generate the Py myc-tagged transgenic lines of PyPF3D7_0506200, PyPF3D7_1241500, and PyPF3D7_07 30200. Genes without their stop codons, together with approximately 1.5 kb sequence upstream from the start codon, were amplified by PCR from Py 17XNL genomic DNA and inserted upstream of the quadruple myc tag in b3D-myc. The plasmids were subsequently linearized with Psr I and integrated into the Py 17XNL genome using standard procedures. This integration strategy created two copies of the target gene, both under the control of the endogenous promoter: the original gene and the myc epitope-tagged gene. | ||||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||||